The 1 analysts offering 12-month price forecasts for Avenue Therapeutics Inc have a median target of 32.00, with a high estimate of 32.00 and a low estimate of 32.00. The median estimate represents a +4,554.55% increase from the last price of 0.69.
The current consensus among 1 polled investment analysts is to Buy stock in Avenue Therapeutics Inc. This rating has held steady since March, when it was upgraded from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.36
Reporting Date Nov 08
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.